Blog

ICH E6 (R3), Demystified Part 5: Essential Records

From Essential Documents to Essential Records: Why Risk-Proportionate Judgment Replaces the Checklist 

For years, essential documents have provided the foundation for demonstrating that clinical trials were conducted appropriately, participants were protected, and study data could be trusted. Under ICH E6(R2), sponsors and investigators worked from an established list of essential documents that defined what needed to be maintained throughout the trial lifecycle. 

ICH E6(R3) builds on that foundation with a more flexible, principle-based approach. The most visible change is terminology: “essential documents” becomes “essential records.” The more significant change is that sponsors and investigators are now expected to determine which records are essential in the context of each specific trial, rather than treating a reference list as a universal checklist. 

This is the fifth chapter in our ICH E6(R3) Demystified series, which translates each core principle and training module into practical steps for sponsors, CROs, and quality leaders. Across seven installments, we show how to move from theory to action using data-driven oversight and explainable analytics, anchored in the real-world application of CluePoints’ Central Monitoring Platform (CMP). 

From Documents to Records: What Has Changed? 

E6(R3) defines essential records as documents, data, and relevant metadata, in any format, that facilitate ongoing trial management and collectively allow evaluation of trial conduct, data reliability, and GCP compliance. 

The broader term reflects how modern trials actually generate evidence. Much of it never exists as a finalized, authored document. Audit trails, system validation outputs, electronic logs, and metadata from eCRF, IRT, and safety systems can all be necessary to reconstruct how trial activities were performed and how data integrity was maintained. 

The requirement sits under Principle 9, which states that clinical trials should generate reliable results. It calls for information that is fit for purpose, efficient and robust processes for managing records, and secure retention of essential records that remain available on request. The detailed expectations appear in Appendix C, with role-specific responsibilities in Section 2.12 (investigator) and Section 3.16 (sponsor). 

What Changed From E6(R2) 

Topic  E6(R2)  E6(R3) 
Terminology  Essential documents  Essential records, including data and metadata 
Approach  Defined list applied across trials  Risk-proportionate judgment based on trial context 
Scope  Primarily authored documents  Includes system-generated evidence such as audit trails and electronic logs 
Records on the reference list  Generally expected for all trials  May not apply, depending on trial design 
Records not on the list  Not explicitly addressed  May still be essential if relevant to the trial 
Quality by Design link  Not explicit  Proportionate trial design leads to a proportionate set of records 

The Checklist Gives Way to Judgment 

Appendix C still includes a reference table of records generally considered essential, but it is not intended to function as a checklist. Section C.3 provides the criteria for deciding essentiality, and the guiding question is straightforward: does this record help demonstrate participant protection, appropriate trial conduct, or the reliability of results? 

The answer depends on the trial’s design, the assessments performed, the systems used, the service providers engaged, and the decisions taken along the way. Some records in the reference table will not exist for a given trial; a study with no service providers will have no service provider oversight records. Other essential records will not appear in the table at all, such as a participant IT help desk log in a decentralized trial. 

One detail is easy to miss: E6(R3) requires the essentiality assessment to take place, but it does not require the assessment itself to be documented. The thinking must happen, and the resulting set of records must be able to stand up to review. 

Why Retaining Everything Is Not the Safe Default 

When documentation requirements are uncertain, keeping every available record can feel like the cautious choice. Modern trials, however, generate enormous volumes of information across clinical, operational, safety, and technology systems, and much of it does not contribute to demonstrating trial quality. Retaining all of it adds operational burden and makes the essential evidence harder to find, which runs counter to the proportionality at the heart of E6(R3). 

This does not lower the bar for rigor. Decisions about which records to discard must also account for other applicable regulatory, legal, contractual, and organizational retention obligations. The aim is for essential evidence to be identified, preserved, and accessible without unnecessary complexity. 

Essentiality in Practice: Two Trials, Different Answers 

The ICH E6(R3) training materials illustrate context-dependent essentiality with two immunoglobulin trials. 

Trial A is a double-blind randomized controlled trial comparing intravenous immunoglobulin (IVIG) with placebo, administered by site staff. Maintaining the blind is central to the trial’s integrity, so emergency unblinding records are essential. They show that treatment allocation was disclosed only when needed for participant safety, and through the proper procedure. Self-administration training records do not apply, because participants never administer treatment themselves. 

Trial B is an open-label, single-arm trial of subcutaneous immunoglobulin (scIG) that participants self-administer at home. Emergency unblinding records are irrelevant because treatment allocation is known to everyone. Participant self-administration training records become essential, because correct technique directly affects both participant safety and data reliability. 

The same record type is essential in one trial and irrelevant in the other. That is why essentiality decisions belong in trial planning, before records start to accumulate. 

Connecting Essential Records to Quality by Design 

In Part 2, we described how teams identify Critical-to-Quality (CtQ) factors during protocol design. The same analysis can drive essential records planning. Once a team knows which processes and data are critical to the trial, it can define the evidence needed to show those activities were performed appropriately. 

This requires cross-functional input. Clinical operations, data management, biostatistics, quality assurance, regulatory affairs, and service providers all generate or manage records that contribute to the overall evidence of trial conduct. Considering essentiality early helps teams identify relevant systems, clarify responsibilities, and agree on record management arrangements before operational complexity increases. 

Making Essential Records Practical With CluePoints 

Risk-based oversight generates its own essential evidence: the CtQ factors a team identified, the risks it assessed, the thresholds it set, and the actions it took when signals emerged. Under E6(R3), that evidence needs to be complete, traceable, and accessible. 

CMP is designed to produce it. The Risk Assessment module documents CtQ factors, associated risks, and controls with full version management and auditability. QTL excursions, root cause analyses, actions taken, and effectiveness evaluations are documented in the QTL module, and follow-up on KRI signals is tracked through the integrated Signals & Actions workflow, supported by timestamped audit trails. When inspectors ask how oversight decisions were made, the rationale and the record of each decision are already connected. 

Questions for Sponsors and CROs 

  • Are we determining essentiality based on trial context? Do our processes account for study design, critical activities, operational risks, and the systems used to conduct the trial? 
  • Are we accounting for system-generated evidence? Have we considered audit trails, metadata, and electronic logs that may be needed to demonstrate trial conduct? 
  • Are essential records considered early enough? Are record requirements evaluated during study planning, rather than addressed retrospectively? 
  • Are responsibilities clear across stakeholders? Do sponsors, investigators, and service providers understand which essential records they generate, manage, and retain? 
  • Can we explain our approach? Even though the assessment does not need to be documented, can our teams articulate why the records they retained are the right ones? 

From Documentation Compliance to Evidence-Based Oversight 

ICH E6(R3) reinforces the role of essential records in demonstrating that trials were conducted appropriately and that their data can be trusted. What changes is how those records are identified: through proportionality, context, and informed judgment rather than a predefined list. This mirrors the broader shift toward risk-based quality management, where attention and resources go to the factors that matter most to participant safety and data reliability. 

The goal is not simply to retain more information. It is to retain the right information, so that it supports meaningful, defensible oversight. 

What’s Next in the Series 

Identifying essential records is the first step. Keeping them complete, accessible, and reliable across the trial lifecycle is the next. 

👉 Coming Next: Part 6: Managing Essential Records 

Explore how E6(R3) addresses version control, metadata, distributed repositories, service provider arrangements, and retention responsibilities. 

Explore the Full Series 

  1. Part 1: Principles & Quality-by-Design 
  1. Part 2: Defining Critical-to-Quality 
  1. Part 3: Quality Tolerance Limits 
  1. Part 4: Informed Consent 
  1. Part 5: Essential Records 
Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Press Release
CluePoints Announced as Fierce Life Sciences Innovation Awards Finalist
Press Release
CluePoints Shortlisted for 2026 Scrip Awards Following 2023 and 2025 Wins
Press Release
CluePoints Launches Three AI-Led Clinical Data Review Capabilities, Co-Innovated with a Top 10 Pharmaceutical Company